PMID- 31901667 OWN - NLM STAT- MEDLINE DCOM- 20201118 LR - 20210201 IS - 1872-7654 (Electronic) IS - 0301-2115 (Print) IS - 0301-2115 (Linking) VI - 245 DP - 2020 Feb TI - Bacterial vaginosis-A brief synopsis of the literature. PG - 143-148 LID - S0301-2115(19)30602-5 [pii] LID - 10.1016/j.ejogrb.2019.12.035 [doi] AB - Bacterial vaginosis (BV) affects women of reproductive age and can either be symptomatic or asymptomatic. Approximately 50 % of women are symptomatic and experience vaginal malodor, discharge, itching and increased vaginal pH. BV can increase the risk of contracting many sexually transmitted infections (STIs) such as human immunodeficiency virus (HIV), Neisseria gonorrhea (NG), Chlamydia trachomatis (CT), Trichomonas vaginalis (TV) and herpes simplex virus-2 (HSV-2). Though effective treatment options do exist, metronidazole or clindamycin, these methods have proven not to be effective long term. The purpose of this review is to summarize current literature on the epidemiology of BV and highlight areas of deficiency in current clinical practice with respect to BV. BV recurrence rates are high, approximately 80 % three months after effective treatment. Furthermore, in some instances treatment is ineffective and BV persists. Literature also documents the relationship between BV and human papillomavirus (HPV). HPV is the most common sexually transmitted infection among young adult women while BV is the most common cause of vaginal symptoms among women of reproductive age. BV is associated with high levels of anaerobic organisms which can damage the vaginal epithelium and increase the risk of HPV infection. Recent research also highlights the role of the vaginal microbiome in BV. The results of this review warrant further exploration into the etiology of BV as well as exploration of more long-term effective treatment and the investigation of prognostic indicators. Additionally, the need for a standard definition of recurrent and persistent BV is recognized. CI - Copyright (c) 2020 Elsevier B.V. All rights reserved. FAU - Coudray, Makella S AU - Coudray MS AD - Department of Epidemiology, Stempel College of Public Health and Social Work, Florida International University, USA. Electronic address: mcoud001@fiu.edu. FAU - Madhivanan, Purnima AU - Madhivanan P AD - Department of Health Promotion Sciences, Mel & Enid Zuckerman College of Public Health, University of Arizona, USA; Internal Medicine, Division of Infectious Diseases, College of Medicine, University of Arizona, Tuscon, Arizona, USA; Public Health Research Institute of India, Mysore, Karnataka, India; Family & Community Medicine, College of Medicine, University of Arizona, Tuscon, Arizona, USA. LA - eng GR - R15 AI128714/AI/NIAID NIH HHS/United States PT - Journal Article PT - Review DEP - 20191224 PL - Ireland TA - Eur J Obstet Gynecol Reprod Biol JT - European journal of obstetrics, gynecology, and reproductive biology JID - 0375672 SB - IM MH - Female MH - Humans MH - Microbiota MH - Recurrence MH - Vagina/microbiology MH - Vaginosis, Bacterial/diagnosis/*epidemiology/microbiology/therapy PMC - PMC6989391 MID - NIHMS1548244 OTO - NOTNLM OT - Bacterial vaginosis OT - Sexually transmitted infections OT - Treatment OT - Vaginal microbiome COIS- Declaration of Competing Interest The authors declare no conflict of interest. EDAT- 2020/01/07 06:00 MHDA- 2020/11/20 06:00 PMCR- 2021/02/01 CRDT- 2020/01/06 06:00 PHST- 2019/05/26 00:00 [received] PHST- 2019/12/09 00:00 [revised] PHST- 2019/12/23 00:00 [accepted] PHST- 2020/01/07 06:00 [pubmed] PHST- 2020/11/20 06:00 [medline] PHST- 2020/01/06 06:00 [entrez] PHST- 2021/02/01 00:00 [pmc-release] AID - S0301-2115(19)30602-5 [pii] AID - 10.1016/j.ejogrb.2019.12.035 [doi] PST - ppublish SO - Eur J Obstet Gynecol Reprod Biol. 2020 Feb;245:143-148. doi: 10.1016/j.ejogrb.2019.12.035. Epub 2019 Dec 24.